Fluoxetine: A Review of its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Use in Older Patients with Depressive Illness

Drugs & Aging

Volumn 6, Issue 1, 1995, Pages 64-84

  Harris, Martin G ^a   Benfield, Paul ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR; AMITRIPTYLINE; CLOMIPRAMINE; FLUOXETINE;

AGED; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DEPRESSION; DRUG EFFECT; DRUG INTERACTION; HUMAN; RANDOMIZED CONTROLLED TRIAL; REVIEW; STATISTICS; SUICIDE;

AGED; AMITRIPTYLINE; CLOMIPRAMINE; DEPRESSIVE DISORDER; DRUG INTERACTIONS; FLUOXETINE; HUMANS; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, ADRENERGIC; SUICIDE;

EID: 0029110308     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.2165/00002512-199506010-00006     Document Type: Article

References (122)

1. Fluoxetine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness
2. Practical psychopharmacologic considerations in depression
3. Modifications of the serotonin system by antidepressant treatments: implications for the therapeutic response in major depression
4. Presynaptic and postsynaptic modifications of the serotonin system by long-term adminis-tration of antidepressant treatments
5. Mode of action of antidepressant drugs
6. Sertraline: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic po-tential in depression and obsessive-compulsive disorder
7. Binding of antidepressants to human brain receptors: focus on newer generation compounds
8. Serotonin receptors in the human brain. I. Characterization and autoradiographic local-ization of 5-HT1A recognition sites: apparent absence of 5-HT1B recognition sites
9. Modern 5-HT receptor classification and 5-HT based drugs
10. Affinities of fluoxetine, its enantiomers, and other inhibitors of serotonin uptake for subtypes of serotonin receptors
11. Guanosine triphosphate activation of brain adenylate cyclase: enhancement by long-term antidepressant treatment
12. β-Adrenergic function in aging: basic mechanisms and clinical implications
13. Physiological changes due to age: pharmacodynamic changes of drug action and implications for therapy
14. 2 receptors in rat brain: an auto-radiographic study
15. Response to SSRI antidepressants correlates with reduction in plasma HVA: pilot study
16. Does fluoxetine exacerbate Parkinson’s disease?
17. A double-bind comparison of the effects of fluoxetine and amitriptyline on cognitive function in elderly depressed patients
18. Antidepressant drugs
19. A comparison of the effect of fluoxetine and trazodone on the cognitive functioning of depressed outpatients
20. Pharmacokinetics of the selective serotonin reuptake inhibitors
21. Accumulation of fluoxetine and norfluoxetine in human brain during therapeutic administration
22. Clinical pharmacokinetics of fluoxetine
23. Fluoxetine: an alternative to the tricyclics in the treatment of major depression?
24. Clinical pharmacokinetics of selective serotonin reuptake inhibitors
25. Guidelines for prescribing psychoactive drugs in the elderly: part 1
26. Age-related changes in hepatic function: implications for drug therapy
27. Depression in the elderly: pharmacokinetics of antidepressants and death from overdose
28. Relationship between antidepressant response and plasma concentrations of fluoxetine and norfluoxetine
29. Clinical pharmacology and pharmacokinetics of fluoxetine: a review
30. Sustained plasma concentrations of fluoxetine and/or norfluoxetine four and eight weeks after fluoxetine discontinuation
31. A double-blind placebo-controlled study of continuation/prophylaxis therapy with dothiepin
32. Drug therapy for geriatric depression
33. Depression in the elderly physically ill: an open study of treatment with the 5-HT reuptake inhibitor fluoxetine
34. Clinical features in depression in old age: a case for minor depression
35. Sodium valproate augmentation of fluoxetine or fluvoxamine effects
36. Fluoxetine and desipramine: a strategy for augmenting anti-depressant response
37. Treatment resistant depression in the elderly: three cases
38. Fluoxetine and depression in the elderly: clinical experience
39. Assessment of quality of life in the treatment of major depressive disorder with fluoxetine, 20 mg, in ambulatory patients aged over 60 years
40. Analysis of the Hamilton Depression Rating Scale factors from a double-blind, placebo-controlled trial of fluoxetine in geriatric major depression
41. Efficacy and tolerability of fluoxetine in the elderly: a double-blind study versus amitriptyline
42. Fluoxetine versus trazodone in depressed geriatric patients
43. Double-blind comparative trials of fluoxetine and doxepin in geriatric patients with major depressive disorder
44. Evaluation of the efficacy, tolerability and therapeutic profile of fluoxetine versus mianserin in the treatment of depressive disorders in the elderly
45. A comparison of fluoxetine and Imipramine in the treatment of outpatients with major depressive disorder
46. A double-blind comparison of paroxetine and fluoxetine in the treatment of geriatric patients with major depression
47. A double-blind comparison of moclobemide and fluoxetine in the treatment of depressive disorders
48. Paroxetine in the elderly depressed patient: randomized comparison with fluoxetine of efficacy, cognitive and behavioural effects
49. Fluoxetine as applied by practising psychiatrists
50. Pharmacotherapy of depressive disorders: a consensus statement
51. How long should elderly patients take antidepressants?
52. Mental health in nursing homes: perspectives on the use of medications
53. Comparative tolerability profiles of the newer versus older antidepressants
54. Adverse reactions as a cause of hospital admission in the aged
55. Adverse effects of antidepressants in the elderly
56. The safety of fluoxetine — an update
57. Fluoxetine in elderly patients: is there cause for concern?
58. Fluoxetine and prolonged seizure
59. Fluoxetine and orgasmic sexual experiences
60. Fluoxetine, fluvox-amine and extrapyramidal tract disorders
61. A case of Parkinson’s disease exacerbated by fluoxetine
62. Parkinsonisme na toevoeging van fluoxetine aan behandeling met neuroleptica of carbamazepine
63. Dysrhythmia associated with fluoxetine treatment in an elderly patient with cardiac disease
64. Bradycardia and hypothermia in an elderly woman receiving fluoxetine
65. Unexpected deaths in depressed medical inpatients treated with fluoxetine
66. Mania during fluoxetine treatment for recurrent depression
67. Mania induced by fluoxetine
68. Cognitive dysfunction associated with fluoxetine
69. Delirium during fluoxetine treatment
70. Syndrome of inappropriate secretion of antidiuretic hormone secondary to fluoxetine
71. More cases of SIADH with fluoxetine
72. Syndrome of inappropriate secretion of antidiuretic hormone due to fluoxetine [letter]
73. Fluoxetine-induced SIADH: a geriatric occurrence
74. The emergence of suicidal ideation and behavior during antidepressant pharmacotherapy
75. The fluoxetine and suicide controversy: a review of the evidence
76. Antidepressant drugs and the emergence of suicidal tendencies
77. Emergence of intense suicidal preoccupation during fluoxetine treatment
78. Suicidal ideation related to fluoxetine treatment [letter]
79. Fluoxetine, akathisia and suicidality: is there a causal connection?
80. Antidepressant induced suicidal ideation
81. Reexposure to fluoxetine after serious suicide attempts by three patients: the role of akathisia
82. Does fluoxetine induce suicidality?
83. Suicidality and fluoxetine: is there a relationship?
84. Safety and efficacy of fluoxetine [letter]
85. Fluoxetine and suicidal preoccupation
86. Comparison of frequencies of suicidal tendencies among patients receiving fluoxetine, lofepramine, mianserin, or trazodone [letter]
87. Fluoxetine and suicide: a meta-analysis of controlled trials of treatment for depression
88. Fluoxetine and suicide
89. Antidepressant medications and the relative risk of suicide attempt and suicide
90. Fluoxetine and suicidal behaviour. Some clinical and theoretical aspects of a controversy
91. Prozac and suicide [letter]
92. Report of a fluoxetine fatality
93. Acute fluoxetine overdose: a report of 234 cases
94. Do some antidepressants promote suicide?
95. The safety of antidepressants
96. Adverse consequences of fluoxetine-MAOI combination therapy
97. The serotonin syndrome
98. Pharmacodynamic and pharmacokinetic interactions between fluoxetine and moclobemide
99. Potential fluoxetine-selegiline interaction [letter]
100. Possible interactions between deprenyl and prozac
101. Elevated antidepressant plasma levels after addition of fluoxetine
102. Fluoxetine induces elevation of desipramine level and exacerbation of geriatric nonpsychotic depression
103. Fluoxetine and norfluoxetine are potent inhibitors of P450IID6 — the source of the sparteine/ debrisoquine oxidation polymorphism
104. Increased plasma tricyclic antidepressant concentrations in two patients concurrently treated with fluoxetine
105. Extremely long plasma half-life of amitriptyline in a woman with the cytochrome P450IID6 29/29-kilobase wild-type allele — a slowly reversible interaction with fluoxetine
106. Inhibition by fluoxetine of cytochrome P450 2D6 activity
107. Serious adverse effects of combining fluoxetine and tricyclic antidepressants [letter]
108. Fluoxetine-induced elevation and prolongation of tricyclic levels in overdose [letter]
109. Effect of fluoxetine on plasma desipramine and 2-hydroxydesipramine
110. Tricyclic antidepressant plasma levels after fluoxetine addition
111. Fluoxetine inhibits desipramine metabolism [letter]
112. Potential interaction between warfarin sodium and fluoxetine [letter]
113. Drug interactions and possible complications of fluoxetine in the elderly
114. Fluoxetine-warfarin interaction
115. Bleeding times and platelet aggregation in volunteers receiving 60 mg of fluoxetine [letter]
116. Fluoxetine-associated potentiation of calcium-channel blockers [letter]
117. Increased carbamazepine plasma concentrations after fluoxetine coadministration
118. The combination of fluoxetine and lithium in clinical practice